What's the Problem?
Our gut harbors a complex micro-community playing a crucial role both in health and disease. An unhealthy lifestyle directly impacts on our gut microbiota causing dysbiosis, which further leads to low grade gut inflammation, the starting point of several diseases including the inflammatory bowel disease, affecting 400 million people in the world, and type II diabetes, with more than 400 million prevalent cases nowadays. With time, some of these patients further develop colorectal cancer, which causes 900,000 deaths per year. Available treatments and interventions against gut inflammation may become refractory with time. Additionally, the variability in the response is high. Indeed, a percentage of patients never responds.
How are they Solving it?
We understand the role of the gut microbiome in the prevention of the most prevalent inflammatory diseases and propose a novel therapeutic approach to reduce the number of non-responders by developing personalized therapies that boost and support microbiota function. Our first development, the microbial functional booster (MFB), a fungal carbohydrate, increased the production of microbial anti-inflammatory molecules up to 500%, and it was 100% effective in our in vitro study. Scalability and clinical validation of this product are now in progress. Since the effect of the MFB was also variable among donors, we are moving to develop a customized product to boost the greatest response in each microbiome. The customized platform is based on an artificial intelligence model that predicts effectiveness from the enzyme profile of an individual microbiota. Taking these biomarkers of microbial function as input, we inquire in our portfolio to find the carbohydrate that better feeds the microbiota of that person and leads to the highest production of anti-inflammatory molecules.
Ocular Bio Design